Create account to read this article for free
Get free access to a limited number of articles.
Fruergaard Jørgensen is leaving – something is wrong
A week ago, Novo Nordisk announced that it had reached an agreement with CEO Lars Fruergaard Jørgensen regarding his resignation. Market challenges and a declining share price are behind the decision to...
Previous chronicles
The EU's new life science strategy – a step in the right direction or just fluff?
Early signs of spring in an otherwise frosty biotech landscape
Trump is once again waving tariff threats – are they just empty words?
Bispecific and Chinese the new black in cancer
The venture capital cycle is complete – we are back where we started
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account